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Abstract Background Effective control of diabetes mel-
litus type 1 (DM1) and type 2 (DM2) can reduce the
development and progression of diabetic complications.
Therefore, patient education should be considered as an
integral part of diabetes management. Objective The aim of
the study was to assess DM patients’ perception of
knowledge for their medication and attitude towards self-
management and pharmacist’s role. Setting The study was
conducted at the diabetes out-patient clinic at the Vienna
General Hospital (AKH), Division of Endocrinology and
Metabolism, Department of Internal Medicine III, Austria.
Method The study was a cross sectional survey using
patient data from a validated patient questionnaire and
medical records. Medical records were evaluated by
applying a medication assessment tool. Main outcome
measure To assess the quality of diabetes self management
the following outcome measures are considered: HbA1c
levels, pre- and post-prandial blood glucose levels, pre-
vention of acute episodes of hypo- and hyperglycaemia,
reduction of macrovascular risk factors, short term quality
of life, adverse effects and treatment tolerance. Results The
present study comprised 225 patients with DM1 and 201
patients with DM2, respectively. In comparison to DM2
patients, cardio- and cerebrovascular diseases were diag-
nosed very rarely in patients with DM1. The risk for these
diseases was higher in patients with other factors of the
metabolic syndrome, in addition. Overall, 118 of these
patients participated in the questionnaire. The level of
positive response on diabetes self-care and knowledge with
respect to medication for the prevention of diabetes com-
plications, glycaemic control, and treatment goals in dia-
betes was 81.8 %. The comparison of patients’ perceptions
of diabetes self-care and knowledge showed differences
among subgroups. Higher perceived knowledge and self-
care apparently was associated with DM1. Additional
findings of this study indicate that patients do not expect
community pharmacists to be integrated in a multidisci-
plinary diabetes care team. Conclusion Although the level
of positive response was found to be high there is still a
minority of patients whose level of comprehension appears
to be insufficient. Intense pharmaceutical care including
patients’ education within a multidisciplinary team could
contribute to improvements in those patients.
Keywords Austria  Diabetes care 
Disease management  Endocrine disorders
Metabolic syndrome  Patient education  Primary care
Impact of findings on practice
• In addition to successful intensified diabetic therapy,
prevention and therapy of comorbidities should be
implemented especially in patients with DM2.
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• Different sub-groups of diabetes patients have different
levels of perceived knowledge and self-care.
• Risk for DM-related macro- and microvascular com-
plications has to be communicated to diabetic patients
in an intelligible manner to improve quality of health
care.
Introduction
According to the International Diabetes Federation (IDF) in
2011 the number of diabetes cases worldwide among the adult
population (aged 20–79 years) was estimated to be 366 mil-
lion in total. It is anticipated that by the year 2030 the number
of estimated cases of diabetes in total will increase to 552
million; that means one adult in ten will have diabetes in 2030.
IDF also estimates that as many as 183 million people are
unaware that they have diabetes [1]. In the IDF Diabetes Atlas
2011, the estimated prevalence of diabetes in Austria was
9.08 % of the adult population which is among the highest
prevalence rates within Europe [1, 2]. Effective control of
diabetes mellitus (DM) in terms of glycaemic levels, blood
pressure and dyslipidaemia can reduce the development and
progression of diabetic complications [3–5].
Patient education in diabetes should be considered as an
integral part of diabetes management [6–8], and is recom-
mended as a necessary component in promoting good dia-
betes control [9]. The main priorities of the national diabetes
plan are primary prevention, special care and services for
people with diabetes, education of people with diabetes for
improved self-care, development of guidelines and protocols
for standards of care, information systems, supply of medi-
cation and equipment, research, diabetes and complications,
prevention of DM2 in obese people, and promoting the
community awareness [10]. One component of the plan
included the introduction of the Disease Management Pro-
gramme (DMP) for DM2 based on the US and German
DMPs for diabetes in 2006. Diabetes education programmes
are offered to reduce the incidence of diabetes by focusing on
lifestyle factors. Information campaigns are developed to
raise awareness, and to encourage people for a medical
check-up. According to American Diabetes Association
(ADA) guidelines, diabetes self-management education is
the ongoing process of facilitating the knowledge, skill, and
ability necessary for diabetes self-care. This process incor-
porates the needs, goals, and life experiences of the person
with DM and is guided by evidence based standards [11].
The value of pharmacological treatment in achieving
and adhering to DM control has clearly been established.
Randomised, controlled trials such as the United Kingdom
Prospective Diabetes Study (UKPDS) demonstrated
undoubtedly that intensive blood glucose control benefits
long-term diabetes complications in patients with DM2 [12].
Moreover, it was shown that tight blood pressure control and
efficient management of diabetes reduces the risk of devel-
oping diabetes complications as well as the financial burden
placed on health care systems, respectively [13]. Therefore,
and taking in consideration the multitude of complications
and risks associated with DM, a multidisciplinary approach
including physicians, pharmacists, nurses, dieticians, and
chiropodists will be required in the management of diabetic
patients.
Aim of the study
The study aimed to assess (1) DM patients’ perception of
knowledge for their medication of DM1, DM2 and co-
morbidities, (2) patients’ attitude towards self-manage-
ment, and (3) pharmacist’s role in diabetes care.
Methods
Study design
The study was a cross sectional survey using patient data
from patient questionnaire and medical records. Literature
review on current standards of diabetes care and delivery,
in particular with regard to medication for prevention of
cardiovascular diseases and blood glucose control was
conducted. The following evidence-based clinical guide-
lines were analysed to devise questions which cover
identified standards in diabetes care: O¨sterreichische Dia-
betes-Gesellschaft (OEDG) [10], American Diabetes
Association (ADA) [11], National Institute for Health and
Clinical Excellence (NICE) [14], and Scottish Intercolle-
giate Guidelines Network (SIGN) guidelines [15].
The paper-based questionnaire was structured into three
parts. The main component of the questionnaire which is
based on a pharmaceutical diabetes model [16], included
medication in the prevention of diabetes complication,
blood glucose control and treatment goals. A second
component was designed in order to assess patients’ per-
ception of the pharmacist’s role in diabetes care. The last
component of the questionnaire included demographic
questions on the participants which could be used to cor-
relate performance among different subgroups of diabetic
patients. Consideration was also given to a primarily closed
questionnaire format since patients had to be enabled to
fully comprehend the questionnaire and to give predefined
answers (YES; NOT SURE; NO). These questions were
expressed as statements, whereby patients indicated their
knowledge. After the completion of the questionnaire the
patient data were anonymised. Overall, the questionnaire
consists of two pages and 25 questions. This condensed
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format was chosen due to the setting at a diabetes out-
patient clinic in Austria’s most frequented hospital.
Setting
The study was conducted at the diabetes out-patient clinic at
the Vienna General Hospital (AKH), Austria. The diabetes
out-patient clinic is part of the Division of Endocrinology
and Metabolism, Department of Internal Medicine III.
The data for the implementation of the medication
assessment tool (MAT) was collected under permissions
granted for a prior study using the MAT from former
studies [17, 18]. The patient questionnaire and protocol for
interviewing the patients were approved by the ethics
committee governing the hospital.
Participants
Overall, the medical records of 225 DM1 and 201 DM2
patients, who attended the out-patient clinic at the Vienna
General Hospital in July/August 2009, were evaluated. Of
these, 118 diabetic patients agreed to complete the ques-
tionnaire and to participate in this part of study. All patients
with DM1 and DM2 with a minimum age of 18, regardless
of gender or origin, identified through their medical records
at the out-patient clinic were eligible for the survey.
Patients additionally could be diagnosed obese and con-
comitantly have cardiovascular disease. Patients with a
diagnosis of gestational diabetes were excluded from the
study. A language barrier was also considered a reason for
exclusion.
Intervention(s)
The procedure of administering the questionnaire and col-
lecting data for the MAT was tested and refined during the
first week. Due to some difficulties in understanding of the
questionnaire, assistance was offered by the investigators.
Relevant information for the questionnaire and the data
collection sheet were obtained from patient medical
records prior to the administration of the questionnaire. The
obtained information for the questionnaire was then vali-
dated during the administration of the questionnaire and
missing data were added. The gathered information was
likewise used to confirm information obtained from med-
ical records for the data collection sheet.
Prior to the administration of the questionnaire patients
were asked if they consent to the use of their anonymised
data. The administration lasted on average for about
10 min, while patients were waiting for their regular DM
review by their consultants. After the completion of the
questionnaire the patient data were anonymised.
Data were entered into SurveyGizmo [19], an online
survey tool which allows to export collected data to text or
spreadsheet for further analysis. All subsequent analysis was
conducted using Microsoft Excel; Fisher’s exact test was
carried out by using the online GraphPad Software [20].
Due to the heterogeneous patient sample, questions were
not applicable for all patients. Data were therefore presented
as level of positive response to individual questions and by
each patient. Level of positive response in percent was
defined as total number of YES counts divided by applica-
bility (summation of YES; NOT SURE; NO COUNTS). The
total number of respondents who completed each question
was indicated as ‘‘n’’, referred to as applicability.
For each MAT criterion six statements were possible:
Not applicable (N/A), YES, Justified non-adherence (NOJ),
Unjustified non-adherence (NOU), Insufficient data for the
qualifier (IDQ), Insufficient data for the standard (IDS).
The percentage of adherence was calculated by dividing
the summation of all criteria rated as YES (if the standard
and the qualifying statement could be applied to the
patient) by the summation of all applicable criteria rated as
YES ? NOU ? IDS multiplied with 100. Levels of
adherence were optional judged as high, intermediate or
low as follows: high level of adherence: C70 %, interme-
diate level of adherence: 50–69.9 %, low level of adher-
ence: \50 %. The final MAT comprised 40 criteria
including 13 criteria for general cardio-preventive mea-
sures, 10 hypertension criteria, 11 criteria for diabetes
management and 6 criteria for anti-obesity medication.
To determine statistically significant differences within
a subgroup, P values were calculated by using Fishers’s
exact test.
Main outcome measure(s)
Principle goals of diabetes management include the preven-
tion of complications and therefore an improvement of quality
of life and avoidance of premature mortality. Those goals can
be achieved by tighter glycaemic control and adequate man-
agement of other risk factors such as high blood pressure,
dyslipidaemia, smoking and obesity. To achieve those goals
patient education plays an important role.
The aim of DM education is to improve patients’
knowledge and skills to allow them to control their own
condition and to integrate self management into their daily
lives. To assess the quality of diabetes management the
following outcome measures are considered: glycated
haemoglobin A1c (HbA1c) levels, pre- and post-prandial
blood glucose levels, prevention of acute episodes of hypo-
and hyperglycaemia, reduction of macrovascular risk fac-
tors, short term quality of life, adverse effects and treat-
ment tolerance.
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This research project was the first attempt to measure
patients’ perceptions of diabetes self-care and knowledge
with respect to medication in a health care setting in Austria.
The questionnaire reflected current guideline recom-
mendations and standards in terms of self-management and
education. The short DM questionnaire was quickly to
administer and evaluate. It was a single test which allowed
the investigators to make subgroup comparisons.
Clinical audit is defined as quality improvement process
that aims to improve patient care and outcomes due to
systematic review of care against explicit criteria. Thereby
outcomes of care are selected and systematically evaluated
against explicit criteria. According to the results the audit is
then used to implement changes or to confirm that current
practice meets the expected level of performance [14]. A
criterion based instrument to test the quality of patient care
is the MAT. The MAT was developed to examine medi-
cation prescribing in definite medical conditions and to
evaluate changes in prescribing which are connected with
pharmaceutical care initiatives. Medication related criteria
are created based on current information from clinical
guidelines [21].
Results
The present study included 225 DM1 and 201 DM2 patients.
Within this study population cardio- and cerebrovascular
diseases were diagnosed very rarely in patients with DM1
compared to patients with DM2 (Tables 1 and 2). Overall, in
DM1 patients there was a tendency for higher prevalence of
macrovascular diseases (angina pectoris, myocardial
infarction, cerebral ischaemia, peripheral artery occlusive
disease, PAOD) when they additionally suffered from
hypertonia, hyperlipidaemia, obesity and poor blood sugar
control (Table 1). In hypertensive DM2 patients the risk for
developing macrovascular diseases was even increased sig-
nificantly. In addition, significantly more patients had per-
cutaneous transluminal angioplasty/coronary artery bypass
grafting (PCTA/CABG) when suffering from hypertension
(Table 1). Similar results were observed for hyperlipidaemic
patients (Table 1). Despite intensified treatment of patients
with DM1 and DM2, microvascular diseases were detected
in an even higher number of patients, and the risk for these
disorders significantly increased with other factors of the
metabolic syndrome (Table 2). Notably, the percentage of
patients suffering from micro- and macrovascular diseases
was higher in DM2 patients with and without co-morbidities
compared to DM1 patients.
These results clearly demonstrate the importance of an
adequate therapy together with education of patients to
improve the outcome. The demographic data of 25 DM1
and 93 DM2 patients, who agreed to complete the ques-
tionnaire and to participate in the survey, are given in
Table 3. Of the 118 patients, 85 % (14 DM1 and 86 DM2)
were aged above 50 years which is line with the reported
age characteristic of DM patients in that DM2 accounts for
80–85 % of patients with diabetes [3].
Responses to questions concerning blood sugar control,
life style advice and medication were collected and eval-
uated for all 118 patients as well as for subgroups as fol-
lows: DM1 and DM2, male and female patients, age \50,
C50, \65, C65 and C75 years. The questions which are
related to criteria of the MAT are listed in the Appendix.
Table 4 shows the percentage of positive responses to
each individual question concerning blood sugar control,
life style advice and medication. The overall level of
positive response to the comprehension questions in the
whole study sample was 81.8 % [CI: 80.1–83.5]. The
majority of questions can be attributed high comprehension
Table 1 Percentage of DM1 (n = 225) and DM2 (n = 201) patients suffering from macrovasular diseases (PAOD, PCTA/CABG, angina
pectoris, myocardial infarction, cerebral ischemia) in presence and absence of major components of the metabolic syndrome
Factors of metabolic
syndrome
PAOD
DM1/DM2
PCTA/CABG
DM1/DM2
Angina pectoris
DM1/DM2
Myocardial infarction
DM1/DM2
Cerebral ischaemia
DM1/DM2
Hypertension 5.5/38.2* 4.4/20.3** 2.2/21.2** 1.1/20.6** 3.3/9.4*
Normotension 0.9/18.2 0.9/4.6 0/4.6 0/4.5 0/0
Hyperlipidaemia 6.2/38.9 4.9/20.3 1.2/20.5 1.2/21.1** 2.5/9.6*
Normolipidaemia 0.8/26.2 0.8/17.1 0.8/17.1 0/4.5 0.8/0
HbA1c [6.5 % 3.6/39.8 3.6/20.2 1.5/21.0 0.7/21.0 1.5/10.2
HbA1c B6.5 % 1.5/30.8 0/15.5 0/17.2 0/14.0 1.5/5.5
BMI C30 kg/m2 7.0/38.0 7.0/16.3 0/20.0 3.5/22.0 7.0/8.0
BMI B30 kg/m2 0/30.8 0/18.3 0/22.6 0/21.7 0/10.2
PAOD (peripheral artery occlusive disease), PCTA (percutaneous transluminal angioplasty), CABG (coronary artery bypass grafting)
Statistically significant differences between hyper- and normotensive patients, patients with and without hyperlipidaemia, patients with good
versus bad long term blood glucose control as well as obese and overweight/normal weight patients are indicated by asterisks (* P \ 0.05,
** P \ 0.01). Statistically significant differences between DM1 and DM2 patients in the respective subgroups are indicated by crosses
( P \ 0.05,  P \ 0.01)
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(C70 % positive responses), especially in respect to blood
sugar control. Moreover, in terms of patients’ blood glu-
cose treatment goals and adjustment of insulin, the
knowledge of patients with DM1 was higher than that of
patients with DM2 (Table 5). A high percentage of patients
seemed to be well informed about the importance of gly-
caemic control, regular exercise and a healthy diet. 93.2 %
of patients remember having received dietary advice and
90.7 % patients stated to be aware of their ideal body
weight. However, 12.9 % were obese and 39 % were
overweight with an actual mean body mass index (BMI)
for the whole sample of 30.0 ± 5.9 kg/m2 (Table 3).
Three questions concerning blood pressure and lipid low-
ering drugs show intermediate comprehension (50–69.9 %
positive responses), and only one question about blood cho-
lesterol is judged as low comprehension (\50 % positive
responses) (Table 4). Only 69.6 % of patients were able to
name all their prescribed medication aimed for prevention of
long term complications of DM. This reflects about 30 % of
patients who are not aware of the aims of their prescribed
drugs. Moreover, the questionnaire indicated that about 30 %
of the patients did not have any knowledge about their cho-
lesterol and/or blood pressure lowering medication. These
findings indicate the need for a more comprehensive educa-
tion and support in this population.
Some questions reveal that female diabetic patients tend
to have more knowledge about their medication and
treatment goals compared to their male counterparts.
However, the differences were not of statistical signifi-
cance (Table 5). The level of positive response for all
subgroups can be considered high, with DM1 patients
being at the top end (85.6 %) and the age group C75 years
(78.8 %) at the lower end (Table 6).
Optimized patients’ education and the provision of
multifaceted interventions can contribute to a better
compliance. Furthermore, it improves patients’ behaviour
Table 2 Percentage of DM1 (n = 225) and DM2 (n = 201) patients
suffering from microvasular diseases (nephropathy, peripheral neu-
ropathy, retinopathy) in presence and absence of major components of
the metabolic syndrome
Factors of
metabolic
syndrome
Nephropathy
DM1/DM2
Peripheral
neuropathy
DM1/DM2
Retinopathy
DM1/DM2
Hypertension 27.4**/58.3 14.5/30.6 45.2**/22.3**
Normotension 3.7/43.2 12.0/30.3 19.3/4.5
Hyperlipidaemia 20.8*/59.8 18.1/31.0 36.9/20.6
Normolipidaemia 9.5/54.5 9.1/27.3 27.0/25.0
HbA1c [6.5 % 12.4/57.9 14.6/31.9 34.4*/23.9*
HbA1c B6.5 % 18.5/58.3 10.2/27.5 22.2/14.6
BMI C30 kg/m2 22.6/50.0 20.2/32.7* 45.0*/17.8
BMI B30 kg/m2 14.8/58.1 16.1/18.3 20.9/11.1
Statistically significant differences between hyper- and normotensive
patients, patients with and without hyperlipidaemia, patients with
good versus bad long term blood glucose control as well as obese and
overweight/normal weight patients are indicated by asterisks
(* P \ 0.05, ** P \ 0.01). Statistically significant differences
between DM1 and DM2 patients in the respective subgroups are
indicated by crosses ( P \ 0.05,  P \ 0.01)
Table 3 Demographic data of
patients with DM1 and DM2,
who completed the
questionnaire. In addition,
information about their
medication and self control of
blood glucose and blood
pressure is given
Parameter All patients
n = 118
DM1
n = 25
DM2
n = 93
Male (n) 63 18 45
Female (n) 55 7 48
Age (years) 62.6 ± 12.7 51.0 ± 13.4 65.7 ± 10.6
Age \50 years (n) 18 11 7
Age C50 and \65 years (n) 43 9 34
Age C65 and \75 years (n) 35 5 30
Age C75 years (n) 22 0 22
Duration of disease (years) 15.4 ± 11.2 22.0 ± 16.2 13.6 ± 8.8
Smokers (%) 20 36 16
BMI (kg/m2) 30.0 ± 5.9 26.6 ± 5.1 30.9 ± 5.9
Patients with hypertension ([130/80 mmHg) (%) 68.8 45.5 91.2
Patients with hyperlipidaemia (%) 65.1 40.5 90.0
Patients with HbA1c [6.5 (%) 68.6 68.5 68.7
Patients on antihypertensive drugs (%) 80.5 56.0 87.1
Patients on statin (%) 60.2 44.0 64.5
Patients on aspirin (%) 49.2 28.0 54.8
Patients on insulin (%) 71.2 100 63.4
Test blood glucose themselves (%) 94.9 100 93.5
Test blood pressure (%) 85.6 76.0 88.2
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which, in turn, will lead to better health outcomes. Within
a multidisciplinary diabetes care team, the pharmacist
could contribute to support the diabetic patients to obtain
their treatment goals. However, as summarized in
Table 7, it is evident that in Austria the pharmacist plays
only a minor role in diabetes care. In the patients’ opinion
the pharmacist is not very well versed in diabetes care,
and therefore they do not consider a pharmacist in dia-
betes care, because they are thought just to dispense
medicines. There were no significant differences between
responses of DM1 and DM2 patients. The question about
patients’ preferred pharmacy revealed that 87.3 % favour
Table 4 Percentage of positive responses of all diabetes patients (n = 118) to each individual question, ranked from highest to lowest positive
response
Question Level of positive
response (%)
[95 % CI]
I have received advice of keeping my blood sugar under control 98.3 [96.0–100]
I am confident in the way I test my blood sugar at home 98.2 [95.8–100]
I am confident about the way I use my insulin injection device 97.6 [94.4–100]
I have received advice on life style (the type of exercise I need to take, smoking cessation) 96.6 [93.3–99.9]
I record my home blood sugar measurement results 93.8 [89.4–98.2]
I have received adequate dietary advice to help me eat healthily 93.2 [88.7–97.8]
I know the name of the insulin type that I adjust for myself 91.7 [85.8–97.6]
I know my ideal body weight 90.7 [85.4–95.9]
I know the names of tablets that I take to control my blood sugar 87.5 [79.4–95.6]
I understand the purpose of my taking aspirin 81.0 [70.9–91.1]
I know my recent hospital test result that my doctor uses to tell me whether my diabetes is well controlled 80.5 [73.4–87.7]
I am confident I can adjust my insulin after testing my blood at home 79.8 [71.2–88.4]
I know what is the ideal blood pressure for me 78.0 [70.5–85.4]
I know the name of the blood test that tells me and my doctor how well controlled my blood sugar
is compared with the last time
75.4 [67.7–83.2]
I know which of my medicines I am taking to control my blood pressure 73.7 [64.8–82.5]
I know the names of all medicines I am taking which aim to prevent the long term effects of diabetes
on heart and blood vessels
69.6 [61.1–78.2]
I know the name of a medicine I take to control my blood cholesterol/blood lipids 69.6 [59.3–80.4]
I know what my blood pressure measurement was last time I came to hospital 67.8 [59.4–76.2]
I know what my blood cholesterol measurement was last time I came to the hospital 34.7 [26.2–43.3]
Table 5 Responses with notable differences (P \ 0.1) in distinct subgroups
Question Level of positive response (%)
[95 % CI] in subgroups
P value
I know the name of the insulin type that I adjust for myself DM1
100 [100]
DM2
88.1 [79.9–96.4]
0.0978
I am confident I can adjust my insulin after testing my blood at home DM1
100 [100]
DM2
71.2 [59.6–82.7]
0.0020
\65
88.4 [78.8–98.0]
C65
70.7 [56.8–84.7]
0.0585
I know the name of the blood test that tells how well controlled my blood sugar is \65
68.9 [57.2–80.5]
C65
82.5 [72.6–92.3]
0.0930
I know the names of all medicines I am taking which aim to prevent the long
term effects of diabetes on heart and blood vessels
Male
62.1 [49.6–74.6]
Female
77.8 [66.7–88.9]
0.0996
I know which of my medicines I am taking to control my blood pressure Male
64.6 [51.1–78.1
Female
83.0 [72.2–93.7]
0.0616
I know my recent hospital test result that my doctor uses to tell me whether
my diabetes is well controlled
Male
87.3 [79.1–95.5]
Female
72.7 [61.0–84.5]
0.0623
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visiting the same pharmacy for the supply of their med-
icine. Therefore, pharmacists are ideally placed to provide
extensive information and additional comprehensive and
continuous support as he/she is in regular contact with
those patients.
Discussion
Besides other aspects the main priorities of the national
diabetes plan include primary prevention, care and ser-
vices for people with diabetes, as well as education of
people with diabetes for improved self-care [10]. Kor-
satko et al. [22] demonstrated that a teaching and treat-
ment program for patients with DM2 who are not using
insulin for glycaemic control was successfully imple-
mented province-wide at the primary health care level.
The present study focused on DM1 and DM2 patients’
perception of their knowledge of DM with respect to their
medication and attitudes towards self-management. Fur-
thermore, patients’ perspective on the role of the phar-
macist in diabetes care in Austria was assessed. The study
identified areas where patients require additional infor-
mation and creates opportunities for future care projects.
Both research instruments, the questionnaire and the
MAT, showed good interaction in respect to diabetes
management, and thus findings of these instruments
proved to be complementary. However, differences
between MAT and questionnaire, especially in compre-
hension of life style matters, were obvious.
The essential goals of education areas include control of
vascular risk factors (blood glucose, blood lipids and blood
pressure), management of diabetes-associated complica-
tions and quality of life. Effective diabetes management can
then be assessed by the following outcome measures: target
glucose levels HbA1c, pre-meal and post-meal blood glu-
cose levels, occurrence of episodes of hypo- and hyper-
glycaemia, reduction of macrovascular risk factors
(dyslipidaemia, high blood pressure, smoking and obesity),
and quality of life, adverse effects and treatment tolerance.
Other important outcomes for educational interventions
focus on diabetes-related knowledge, motivation and
improved anxiety or depression, respectively [14].
Compared to DM2 patients in the present and a former
study [23], macro- and microvascular diseases were diag-
nosed very rarely in patients with DM1. Besides intensified
therapy, the reason for this finding might be due to the lower
age of DM1 patients. Although, DM1 patients were suffering
from DM much longer than DM2 patients, they had less co-
morbidity. Obviously, patients with DM1 are more aware of
the risks of DM, and thus they accept to live a more disci-
plinary life. This was also reflected by the level of positive
response for almost all questions in the survey that was
highest for DM1 patients. The general level of positive
responses to DM self-management and knowledge appears
to be high. The findings of this study suggest that diabetic
patients believe to have a high overall knowledge about
medication used for the prevention of diabetes complica-
tions, as well as glycaemic control and treatment goals in
diabetes. In fact, our findings are in line with several studies,
which have shown that proper and adequate knowledge of
DM was associated with good DM control [24–26].
Although the level of positive responses can be considered
high, the present study revealed that knowledge is declining
with age, which confirms other reports [27, 28]. Still, there is
a minority of patients whose level of comprehension is
considered to be low or intermediate, in particular concern-
ing general cardio-preventive criteria. Although patients are
convinced that they have a good comprehension of self-
Table 6 Overall level of positive responses for the subgroups
Subgroup Level of positive response (%)
[95 % CI] in subgroups
DM1 85.6[82.2–89.0]
DM2 80.8[78.9–82.8]
Male 82.2[79.9–84.5]
Female 81.4[78.9–83.9]
Age \65 years 81.5[79.1–83.9]
Age C65 years 82.2[79.8–84.6]
Age C75 years 78.8[74.7–83.0]
Table 7 Patients’ perceptions
about available support of the
pharmacist in diabetes care
(n = 118). Values are given in
percent
How often the pharmacy supports patients with regard to Often Sometimes Seldom Not at all
Checks my blood pressure 0.8 4.2 1.7 93.2
Questions about diabetes 0 9.3 1.7 89.0
Questions about my diabetes medication 0 9.3 0.8 89.8
Understanding of my treatment goals 0 4.2 0.8 94.9
Questions about other medication I am taking 5.1 29.7 6.8 58.5
Understanding of the changes I must make to my life style 2.5 8.5 1.7 87.3
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management, this is not necessarily reflected by a behav-
ioural change as shown by the comparison of ideal BMI to
actual BMI (30.0 kg/m2). Moreover, patients’ perceptions of
ideal blood pressure and blood lipid profile revealed that only
a minority of patients indicated blood pressure and lipid level
targets that were within the target ranges. This is the more
important as it is evident that the risk for the development of
micro- and macrovascular disorders positively correlates
with hypertension, dyslipidaemia and body weight, despite
good blood sugar control. So, in addition to the successful
intensified diabetic therapy, knowledge about prevention
and therapy of co-morbidities should be forced.
Intense pharmaceutical care within a multidisciplinary
team can contribute to improvement in diabetes self-care
and knowledge. Pharmacists are involved in diabetes care
through traditional core activities such as health promotion
and education for the diabetes patient. Pharmacist
involvement in diabetes care in the hospital setting
revealed a significant reduction of blood pressure and
blood lipids in patients who could previously not meet their
treatment targets. This improvement was sustained after
discharge [29]. Furthermore, pharmacist intervention
compared to usual diabetes care produced significant
reductions in the risk of cerebrovascular accident and
coronary heart disease in hypertensive DM2 patients [30].
Although studies of community pharmacy based-interven-
tions on diabetes control, adherence, medication problems
and patient knowledge in DM2 found limited evidence for
these interventions, they suggested that educating patients
and discussing patients’ perceptions of DM can contribute
to effective pharmacists’ interventions. Additionally, it was
shown that patients accept extended services by pharma-
cists, however, they do not expect them to be involved in
diabetes care [31–33].
In Austria, regional pilot projects [34] for prevention
and diabetes care, started in 2006. Screening by pharma-
cists covered blood glucose, blood pressure, cholesterol,
abdominal girth, weight and lung function. If one of the
levels were out of range, a referral to the general practi-
tioner was recommended. In particular, pharmacists should
be involved in diabetes care concerning medication prob-
lems. However, findings of the present study indicate that
patients in Austria do not expect pharmacists to be inte-
grated in a multidisciplinary diabetes care team. The
majority of the patients tend to use the same pharmacy for
the supply of their medication. As the pharmacist is in
regular contact with those patients, he/she is ideally placed
to provide comprehensive and continuous support. This
might implicate an opportunity for future pharmaceutical
care projects.
Conclusion
Diabetes care is a complex, time-consuming process and its
success is mainly dependent on the participation of the
patient. Education represents a cornerstone in diabetes care
and should enable the patient to control diabetes by self-
monitoring his/her condition. Based on our findings, the
general level of positive responses to DM self-management
and knowledge was high. Compared to DM2 patients, DM1
patients had less co-morbidity and were more aware of the
risks of DM. Furthermore, they accepted to live a more
disciplinary life. Overall, DM1 patients and younger
patients tend to have higher knowledge and better adher-
ence to medication than DM2 patients and patients
C75 years. Despite intensified treatment of DM, the risk
for macro- and microvascular diseases significantly
increased with other factors of the metabolic syndrome.
The awareness of this fact has to be communicated to
diabetic patients in an intelligible manner to improve
quality of health care.
Funding None.
Table 8 Questions related to criteria of MAT and level of adherence (L, low, \50 %; I, intermediate, 50–69 %; H. high, [70 %)
MAT criteria Questionnaire
(A) General cardiopreventive criteria
Patient diagnosed with diabetes and with at least one additional CV
risk factor is prescribed aspirin
L I understand the purpose of my taking aspirin H
Patient aged C50 years is prescribed aspirin L
Patient aged \50 years with significant CV risk factors is prescribed
aspirin
L
Patient aged C40 years is prescribed a statin I I know the name of a medicine I take to control my blood
cholesterol/blood lipids
I
Patient aged \40 years old with high CV risk factor profile ([20 %
in 10 years) is prescribed a statin
L
Patient who is prescribed a statin has achieved LDL levels\2.6 mM L
Patient who is prescribed a statin has achieved a TC\4 mM or LDL
levels \2 mM
L I know what my blood cholesterol measurement was last time I
came to the hospital
L
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Table 8 continued
MAT criteria Questionnaire
Patient with CVD or history of MI is prescribed a beta-blocker
Patient with a history of MI is prescribed an ACE-I or ARB
Patient with microalbuminuria or proteinuria is prescribed an ACE-I
or ARB
H
H
H
I know the names of all medicines I am taking which aim to
prevent the long term effects of diabetes on heart and blood
vessels
I
(B) Hypertension criteria
Diabetes patient diagnosed with hypertension is prescribed
antihypertensive drug therapy
H I know what my blood pressure measurement was last time I
came to hospital
I
Patient WITHOUT co-existing kidney, eye or CV damage AND/OR
without two or more features of the metabolic syndrome has
achieved blood pressure control of B140/80 mmHg (DM2) or
B135/85 mmHg (DM1)
L I know the ideal blood pressure for me H
Patient WITH co-existing kidney, eye or CV damage AND/OR
without two or more features of the metabolic syndrome has
achieved blood pressure control of B130/80 mmHg
L
Patient prescribed aspirin has achieved a blood pressure \145/
90 mmHg
L
Patient with hypertension is prescribed an ACE-I or an ARB H I know which of my medicines I am taking to control my blood
pressure
H
Patient on ACE-I or an ARB and uncontrolled blood pressure is
added a CCB and/or a diuretic
H
Patient with treated hypertension is NOT prescribed a combination of
thiazide diuretic and beta blocker
H
Patient diagnosed with hypertension and on thiazide diuretic as a
single antihypertensive agent does NOT have gout, CrCL \30 ml/
min, hypokalaemia, dyslipidaemia
H
(C) Diabetes management
Patient stabilised on insulin has achieved HbA1c \7.5 % or a
documented individual agreed target
H I have received advice of keeping my blood sugar under control H
I record my home blood sugar measurement results H
I am confident in the way I test my blood sugar at home H
I know my recent hospital test result that my doctor uses to tell
me whether my diabetes is well controlled
H
Patient with a diagnosis of diabetes of at least 15 months has had two
HbA1c measurements taken at least twice within the past
15 months
H I know the name of the blood test that tells me and my doctor
how well controlled my blood sugar is compared with the last
time
H
Patient requiring oral antidiabetic agent and without apparent
contraindication/intolerance is prescribed metformin
H Know the names of tablets that I take to control my blood sugar H
Patient NOT on metformin due to apparent contraindication/
intolerance is prescribed a sulfonurea
H
Patient prescribed highest recommended/tolerated dose of metformin
and whose glucose control remains inadequately controlled is
additionally prescribed a sulfonurea
H
Patient prescribed a thiazolidinedione and metformin OR sulfonurea
because of apparent contraindication/intolerance of sulfonurea OR
metformin OR inadequate diabetes control
H
Patient who does not accept insulin and who is on a DPP4-inhibitor
OR thiazolidinedione has prescribed it with metformin and
sulfonurea
I
Patient prescribed metformin and sulfonurea and whose glucose
levels remain insufficiently controlled is prescribed additional
insulin
H I am confident about the way I use my insulin injection device
I know the name of the insulin type that I adjust for myself
I am confident I can adjust my insulin after testing my blood at
home
H
H
H
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